Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved OTC

6

Possibly Marketed Outside US

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Methotrexate

5

Streptococcus mutans

5

T cell mediated immunity

5

Zinc transporter ZIP1

5

Zinc transporter ZIP2

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

7

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

6

2019

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Zinc deficiency

6

Acute myeloid leukemia

5

Breast cancer

5

Caries

5

Diaper dermatitis

5

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

6

Primary

6

Secondary

5

Curative

1

Palliative

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

5

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Smithson, R.

5

Goorley, J.T.

1

Hamari Chemicals Ltd.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

8

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

8

DAILYMED

8

DSLD

8

FDA UNII

8

PUBCHEM

8

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

2

DERMATOLOGICALS

2

CARDIOVASCULAR SYSTEM

1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

MEDICATED DRESSINGS

2

MINERAL SUPPLEMENTS

1

OPHTHALMOLOGICALS

1

OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

1

VASOPROTECTIVES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

MEDICATED DRESSINGS

2

AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE

1

ANTIINFECTIVES

1

OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

1

OTHER MINERAL SUPPLEMENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Zinc bandages

2

Other agents for treatment of hemorrhoids and anal fissures for topical use

1

Other antiinfectives

1

Various alimentary tract and metabolism products

1

Zinc

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "Dietary Supplement Label Database|Mineral|Zinc" in comments (approximate match)

Showing 1 - 8 of 8 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ZINC CATION

13S1S8SF37

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

POLAPREZINC

0WA1B15A1Z

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2019

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Heat shock 70 kDa protein

Vascular endothelial growth factor receptor 1

Platelet-derived growth factor receptor beta

Tumor necrosis factor

Polaprezinc is a zinc-containing molecule and used for the therapy of gastric ulcer. It has been reported that this compound inhibits the induction of TNF-a as well as cellular signaling of TNF-a. Polaprezinc has been shown to exert an anti-oxidant p...

roperty in a tube experiment and accelerate the healing of gastric ulcer in humans. Polaprezinc inhibited EtOH-induced cytochrome c reduction. Protection by polaprezinc was microscopically associated with the prevention of monolayer disruption. In an animal model of chemotherapy-induced oral mucositis polaprezinc improves the recovery from 5-fluorouracil–induced oral mucositis in hamsters. Polaprezinc ameliorates mucosal ulceration in acetic acid-induced experimental oral mucositis in hamsters. Polaprezinc is potentially useful for prevention of oral mucositis and improvement of quality of life without reducing the tumor response. Polaprezinc is in phase II clinical trial for the treatment of taste disorders.

ZINC ASPARTATE

4OC7QTI23H

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2019

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

T cell activation involved in immune response

Conditions:

Zinc deficiency

Ischemia-reperfusion injury

Multiple sclerosis

Myringosclerosis

Acrodermatitis enteropathica

Zinc aspartate is an approved drug, used to treat zinc deficiency in humans. Zinc aspartate regulates the production of the growth hormone and sex hormones (it is necessary for the production of sperm cells and egg cells). It reduces the body’s susce...

ptibility to infections and allergies. It promotes the proper secretion of insulin by the pancreas. Zinc deficiency causes: disorders in the functioning of the skin, the digestive system, the nervous system, the immunological system, and the skeletal system. Significant zinc deficiency can cause dwarfism and genital underdevelopment. Zinc aspartate suppresses experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS), as well as effector T cell functions in vitro.

ZINC

J41CSQ7QDS

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

C55-isoprenyl pyrophosphate

Conditions:

Superficial infections of the external eye and its adnexa caused by susceptible bacteria

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitr...

acin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

ZINC GLYCINATE

681VJX72FE

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC CITRATE

K72I3DEX9B

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC ACETATE

FM5526K07A

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC GLUCONATE

U6WSN5SQ1Z

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1